SCHEDULE: Kezar Life Sciences Merger Completed, Tang Capital Reports Zero Ownership

Kezar Life Sciences announced the completion of its merger with Aurinia Pharma U.S., Inc., resulting in the cancellation of all outstanding common stock, with Tang Capital entities reporting no beneficial ownership post-merger.

Summary

• Kezar Life Sciences, Inc. has completed its merger with Aurinia Pharma U.S., Inc. and its subsidiary, Aurinia Merger Sub, Inc., effective May 11, 2026.
• As a result of the merger, all issued and outstanding shares of Kezar Life Sciences' Common Stock were cancelled.
• Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., Tang Capital Partners IV, Inc., and Concentra Biosciences, LLC (collectively, the 'Reporting Persons') have amended their Schedule 13D filing.
• The Reporting Persons now report zero shares beneficially owned and zero percent of the class represented by the amount in Row (11).
• The Reporting Persons ceased to be beneficial owners of 5% or more of Kezar Life Sciences' Common Stock on May 11, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on a completed merger and the subsequent zeroing out of beneficial ownership by a reporting party, rather than providing new operational or financial performance data.

Positives

• The merger between Kezar Life Sciences and Aurinia Pharma has been successfully completed, fulfilling a significant corporate event.
• The filing confirms the cessation of beneficial ownership of 5% or more by the Reporting Persons, indicating a resolution of their stake in Kezar Life Sciences.

Negatives

• All outstanding shares of Kezar Life Sciences' Common Stock were cancelled as part of the merger, meaning existing shareholders no longer hold equity in the company.
• The Reporting Persons no longer hold any beneficial ownership in Kezar Life Sciences.

Risks

• Shareholders of Kezar Life Sciences prior to the merger had their shares cancelled, representing a complete loss of their investment in the company's common stock.
• The merger itself may have involved risks related to integration, regulatory approvals, and market reception, though these are not detailed in this specific filing.

Future Outlook

The filing primarily reports on a completed event (the merger) and the resulting change in beneficial ownership. There are no forward-looking statements or guidance provided regarding future operations of the merged entity or the future activities of the Reporting Persons.

Management Comments

• The Reporting Persons have amended and supplemented Items 4 and 5 of the Statement.
• Except as amended, the original disclosure set forth in the Statement shall remain unchanged.
• The Reporting Persons do not own any shares of the Issuer's Common Stock as of the date hereof.
• No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons.

Industry Context

StockSavvy.ai notes that mergers and acquisitions are common in the biotechnology and pharmaceutical sectors as companies seek to consolidate pipelines, gain market share, or achieve economies of scale. The cancellation of shares is a standard outcome for the target company in a merger where it is absorbed by the acquirer.

Stakeholder Impact

• Shareholders of Kezar Life Sciences: Their shares were cancelled as part of the merger, meaning they no longer hold equity in the company and their investment in Kezar Life Sciences common stock is effectively concluded.
• Tang Capital entities: Have ceased to be beneficial owners of 5% or more of Kezar Life Sciences' common stock, signifying the end of their significant stake.
• Aurinia Pharma: Has successfully acquired Kezar Life Sciences, integrating its assets and operations.

Next Steps

• The merger between Kezar Life Sciences and Aurinia Pharma has been completed.
• The Reporting Persons have updated their beneficial ownership status to reflect zero holdings in Kezar Life Sciences.

Key Dates

Keywords

Kezar Life Sciences, Aurinia Pharma, Merger, Schedule 13D, Tang Capital, SEC Filing, Corporate Action, Stock Cancellation